<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685278</url>
  </required_header>
  <id_info>
    <org_study_id>Military Hospital of Tunis</org_study_id>
    <nct_id>NCT04685278</nct_id>
  </id_info>
  <brief_title>Anticardiolipin Autoantibodies and Mortality in Septic Patients</brief_title>
  <acronym>aCLsepsis</acronym>
  <official_title>Anticardiolipin Autoantibodies as Useful Biomarker for the Prediction of Mortality in Septic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Military Hospital of Tunis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Military Hospital of Tunis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The detection of antiphospholipid antibodies (aPL) is of interest because of their importance&#xD;
      in the pathogenesis of arterial or venous thrombosis and their responsibility for a wide&#xD;
      spectrum of clinical manifestations such as infection. The aim of the study was to assess the&#xD;
      performance of antiphospholipid antibodies biomarker to predict in- hospital mortality in&#xD;
      intensive care unit (ICU) septic patient's.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the investigators conducted a prospective single-center observational study including&#xD;
      consecutive critically ill septic adults admitted to the intensive care unit. Clinical and&#xD;
      laboratory data including chemiluminescence immunoassay for antiphospholipid antibodies&#xD;
      [anticardiolipin (aCL), antiphosphatidylserine (aPS)] were obtained. Blood samples were&#xD;
      collected on days 1, 3, 5, 8 and 10 of hospitalization. The primary study endpoint was ICU&#xD;
      mortality defined as death before ICU discharge. Secondary end points included correlation&#xD;
      between SOFA score and biological parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>mortality at day 14 of hospitalization</time_frame>
    <description>Mortality was defined as death before ICU discharge Multivariate logistic regression modeling will beperformed to found factors associated with higher mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between SOFA score and antiphospholipid antibodies.</measure>
    <time_frame>on days 1, 3, 5, 8 and 10 of hospitalization</time_frame>
    <description>assess correlations between serum levels of both aCL and aPS and SOFA score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Morality</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients, admitted to the ICU for sepsis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients, admitted to the ICU for sepsis and older than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  clinical history of antiphospholipid syndrome&#xD;
&#xD;
          -  auto-immune diseases&#xD;
&#xD;
          -  immunosuppressive treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iheb Labbene, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Military Hospital of Tunis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zied Hajjej, Pr</last_name>
    <phone>0021620358907</phone>
    <email>hajjej_zied@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Military Hospital of Tunisia</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iheb Labbene, Pr</last_name>
      <phone>0021698336213</phone>
      <email>iheb.labbene@fmt.utm.tn</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Military Hospital of Tunis</investigator_affiliation>
    <investigator_full_name>Hajjej Zied</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>anti-phospholipid</keyword>
  <keyword>sepsis</keyword>
  <keyword>intensive care unit</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

